SecBot SecBot
SECBOTREPLAY Home › Report › THRM

THRM · Gentherm received FDA 510(k) clearance for its ThermAffyx Patient…

Gentherm Inc · PRESS-RELEASE filed Jul 20, 2026 at 16:00 ET

At the news

BULLISHIMPACT 6/10

PRESS-RELEASE filed Jul 20, 2026 at 16:00 ET

Gentherm received FDA 510(k) clearance for its ThermAffyx Patient Safety System, a Class II medical device combining active patient warming, securement, and pressure reduction for robotic-assisted surgeries. Revenue generation is expected to begin in Q3 2026, with product trials starting in August. This expands Gentherm's medical portfolio beyond automotive thermal management, but the near-term financial impact is modest relative to the company's ~$1.5B annual revenue base.

  • FDA 510(k) clearance for ThermAffyx Patient Safety System, a Class II medical device
  • Device combines active patient warming, securement, and pressure reduction for robotic-assisted surgeries
  • Product trials begin August 2026; revenue expected to commence in Q3 2026
  • Addresses a gap where only 17-21% of patient body surface area is available for forced-air warming in robotic procedures

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access